AU2003213242A1 - Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents - Google Patents
Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents Download PDFInfo
- Publication number
- AU2003213242A1 AU2003213242A1 AU2003213242A AU2003213242A AU2003213242A1 AU 2003213242 A1 AU2003213242 A1 AU 2003213242A1 AU 2003213242 A AU2003213242 A AU 2003213242A AU 2003213242 A AU2003213242 A AU 2003213242A AU 2003213242 A1 AU2003213242 A1 AU 2003213242A1
- Authority
- AU
- Australia
- Prior art keywords
- migraine
- topiramate
- group
- formula
- serotonin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000019695 Migraine disease Diseases 0.000 title claims description 181
- 206010027599 migraine Diseases 0.000 title claims description 161
- 229940125684 antimigraine agent Drugs 0.000 title claims description 39
- 239000002282 antimigraine agent Substances 0.000 title claims description 39
- 238000011262 co‐therapy Methods 0.000 title claims description 21
- 239000001961 anticonvulsive agent Substances 0.000 title claims description 19
- 238000011282 treatment Methods 0.000 title description 71
- 230000001773 anti-convulsant effect Effects 0.000 title description 5
- 229960003965 antiepileptics Drugs 0.000 title description 5
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 92
- 229960004394 topiramate Drugs 0.000 claims description 88
- 238000000034 method Methods 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 49
- -1 methylenedioxy group Chemical group 0.000 claims description 44
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical group CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 claims description 35
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 239000000935 antidepressant agent Substances 0.000 claims description 21
- 229940005513 antidepressants Drugs 0.000 claims description 21
- 239000002876 beta blocker Substances 0.000 claims description 21
- 229940097320 beta blocking agent Drugs 0.000 claims description 21
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 20
- 206010028813 Nausea Diseases 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 230000008693 nausea Effects 0.000 claims description 19
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 18
- 206010034960 Photophobia Diseases 0.000 claims description 15
- 206010054956 Phonophobia Diseases 0.000 claims description 14
- 230000003474 anti-emetic effect Effects 0.000 claims description 14
- 239000002111 antiemetic agent Substances 0.000 claims description 14
- 229940125683 antiemetic agent Drugs 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 13
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 13
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 239000000480 calcium channel blocker Substances 0.000 claims description 12
- 229910052760 oxygen Chemical group 0.000 claims description 12
- 239000001301 oxygen Chemical group 0.000 claims description 12
- 102000003797 Neuropeptides Human genes 0.000 claims description 11
- 108090000189 Neuropeptides Proteins 0.000 claims description 11
- 229940035676 analgesics Drugs 0.000 claims description 11
- 239000005557 antagonist Substances 0.000 claims description 11
- 239000000730 antalgic agent Substances 0.000 claims description 11
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 10
- 229940121356 serotonin receptor antagonist Drugs 0.000 claims description 10
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims description 9
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims description 9
- 229940076279 serotonin Drugs 0.000 claims description 9
- 229960005254 naratriptan Drugs 0.000 claims description 7
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 229960003708 sumatriptan Drugs 0.000 claims description 7
- 229960002133 almotriptan Drugs 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 229960002472 eletriptan Drugs 0.000 claims description 6
- 229960002284 frovatriptan Drugs 0.000 claims description 6
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229960000425 rizatriptan Drugs 0.000 claims description 6
- 229960001360 zolmitriptan Drugs 0.000 claims description 6
- 125000002009 alkene group Chemical group 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 229960004255 nadolol Drugs 0.000 claims description 5
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 5
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 5
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical group C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 5
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical group C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 4
- 229960001653 citalopram Drugs 0.000 claims description 4
- 239000002151 riboflavin Substances 0.000 claims description 4
- 229960002477 riboflavin Drugs 0.000 claims description 4
- 235000019192 riboflavin Nutrition 0.000 claims description 4
- 229960004688 venlafaxine Drugs 0.000 claims description 4
- 239000003420 antiserotonin agent Substances 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims 3
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 claims 3
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims 3
- 101150009274 nhr-1 gene Proteins 0.000 claims 3
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims 3
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 3
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 description 80
- 231100000869 headache Toxicity 0.000 description 76
- 229940079593 drug Drugs 0.000 description 59
- 239000003814 drug Substances 0.000 description 59
- 239000000902 placebo Substances 0.000 description 39
- 229940068196 placebo Drugs 0.000 description 39
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 38
- 230000008859 change Effects 0.000 description 36
- 206010015037 epilepsy Diseases 0.000 description 34
- 208000024891 symptom Diseases 0.000 description 33
- 229940127558 rescue medication Drugs 0.000 description 31
- 238000004448 titration Methods 0.000 description 28
- 230000000694 effects Effects 0.000 description 25
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 24
- 206010003791 Aura Diseases 0.000 description 24
- 208000002193 Pain Diseases 0.000 description 23
- 238000011321 prophylaxis Methods 0.000 description 22
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 20
- 229960005489 paracetamol Drugs 0.000 description 20
- 230000009467 reduction Effects 0.000 description 19
- 238000012423 maintenance Methods 0.000 description 18
- 238000011287 therapeutic dose Methods 0.000 description 15
- 208000000060 Migraine with aura Diseases 0.000 description 14
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 14
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 13
- 230000002265 prevention Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 11
- 206010027603 Migraine headaches Diseases 0.000 description 11
- 229960001138 acetylsalicylic acid Drugs 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 10
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 10
- 229960001948 caffeine Drugs 0.000 description 10
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 10
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 206010047700 Vomiting Diseases 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 9
- 230000008673 vomiting Effects 0.000 description 9
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 8
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 8
- 229960002546 butalbital Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 229940095990 inderal Drugs 0.000 description 7
- 230000000053 inderal effect Effects 0.000 description 7
- 238000002483 medication Methods 0.000 description 7
- 206010052787 migraine without aura Diseases 0.000 description 7
- AMKVXSZCKVJAGH-UHFFFAOYSA-N naratriptan Chemical compound C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AMKVXSZCKVJAGH-UHFFFAOYSA-N 0.000 description 7
- 239000008177 pharmaceutical agent Substances 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229960004126 codeine Drugs 0.000 description 6
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 6
- 229960001140 cyproheptadine Drugs 0.000 description 6
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- PWVXXGRKLHYWKM-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 PWVXXGRKLHYWKM-LJQANCHMSA-N 0.000 description 6
- 229960001186 methysergide Drugs 0.000 description 6
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 6
- FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 6
- 229940043274 prophylactic drug Drugs 0.000 description 6
- 239000012658 prophylactic medication Substances 0.000 description 6
- ULFRLSNUDGIQQP-UHFFFAOYSA-N rizatriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CN1C=NC=N1 ULFRLSNUDGIQQP-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 6
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 5
- 101000703464 Homo sapiens SH3 and multiple ankyrin repeat domains protein 2 Proteins 0.000 description 5
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 5
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 5
- 102100030680 SH3 and multiple ankyrin repeat domains protein 2 Human genes 0.000 description 5
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 229940047493 celexa Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- XCGSFFUVFURLIX-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 XCGSFFUVFURLIX-VFGNJEKYSA-N 0.000 description 5
- 229960004943 ergotamine Drugs 0.000 description 5
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 5
- 229960003712 propranolol Drugs 0.000 description 5
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 5
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 4
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 4
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 4
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 4
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 4
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000021017 Weight Gain Diseases 0.000 description 4
- 239000004015 abortifacient agent Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229940097488 corgard Drugs 0.000 description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 4
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 4
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 4
- 229960001253 domperidone Drugs 0.000 description 4
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 4
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 4
- 229960000326 flunarizine Drugs 0.000 description 4
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 4
- 229960000240 hydrocodone Drugs 0.000 description 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 229960004503 metoclopramide Drugs 0.000 description 4
- WSXKZIDINJKWPM-IBGZLQDMSA-N n,6-dimethylhept-5-en-2-amine;(2s,3r,4s,5r)-2,3,4,5-tetrahydroxyhexanedioic acid Chemical compound CNC(C)CCC=C(C)C.CNC(C)CCC=C(C)C.OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O WSXKZIDINJKWPM-IBGZLQDMSA-N 0.000 description 4
- CVXJAPZTZWLRBP-MUUNZHRXSA-N n-[(2r)-1-[acetyl-[(2-methoxyphenyl)methyl]amino]-3-(1h-indol-3-yl)propan-2-yl]-2-(4-piperidin-1-ylpiperidin-1-yl)acetamide Chemical compound COC1=CC=CC=C1CN(C(C)=O)C[C@H](NC(=O)CN1CCC(CC1)N1CCCCC1)CC1=CNC2=CC=CC=C12 CVXJAPZTZWLRBP-MUUNZHRXSA-N 0.000 description 4
- 229940097496 nasal spray Drugs 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 229960004572 pizotifen Drugs 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 229960004605 timolol Drugs 0.000 description 4
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 4
- 229960000604 valproic acid Drugs 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- YKPUWZUDDOIDPM-VURMDHGXSA-N zucapsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O YKPUWZUDDOIDPM-VURMDHGXSA-N 0.000 description 4
- 229960002860 zucapsaicin Drugs 0.000 description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940003025 amerge Drugs 0.000 description 3
- 229940003357 axert Drugs 0.000 description 3
- CUETXFMONOSVJA-KLQYNRQASA-N butanedioic acid;(6r)-6-(methylamino)-6,7,8,9-tetrahydro-5h-carbazole-3-carboxamide;hydrate Chemical compound O.OC(=O)CCC(O)=O.N1C2=CC=C(C(N)=O)C=C2C2=C1CC[C@@H](NC)C2 CUETXFMONOSVJA-KLQYNRQASA-N 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 229940075925 depakote Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229960002464 fluoxetine Drugs 0.000 description 3
- 229940090436 imitrex Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 229940103177 maxalt Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229940090008 naprosyn Drugs 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- 229960001158 nortriptyline Drugs 0.000 description 3
- 229960000482 pethidine Drugs 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 229940035613 prozac Drugs 0.000 description 3
- 229940070979 relpax Drugs 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 229940003675 zomig Drugs 0.000 description 3
- CCIWVEMVBWEMCY-RCFOMQFPSA-N (2s)-1-[(3as,4s,7as)-4-hydroxy-4-(2-methoxyphenyl)-7,7-diphenyl-1,3,3a,5,6,7a-hexahydroisoindol-2-yl]-2-(2-methoxyphenyl)propan-1-one Chemical compound COC1=CC=CC=C1[C@H](C)C(=O)N1C[C@H](C(CC[C@@]2(O)C=3C(=CC=CC=3)OC)(C=3C=CC=CC=3)C=3C=CC=CC=3)[C@H]2C1 CCIWVEMVBWEMCY-RCFOMQFPSA-N 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 2
- BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 description 2
- 108010073488 1-(N(2)-(3,4-dibromo-N-((4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl)carbonyl)tyrosyl)lysyl)-4-(4-pyridinyl)piperazine Proteins 0.000 description 2
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 2
- JQSAYKKFZOSZGJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 description 2
- LOGVKVSFYBBUAJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine;hydron;dichloride Chemical compound Cl.Cl.COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 LOGVKVSFYBBUAJ-UHFFFAOYSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- BCHLTFOMLWCYIS-UHFFFAOYSA-N 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxybenzamide;n-(4-hydroxyphenyl)acetamide;hydrochloride Chemical compound Cl.CC(=O)NC1=CC=C(O)C=C1.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC BCHLTFOMLWCYIS-UHFFFAOYSA-N 0.000 description 2
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 2
- 241001415674 Coccoloba rugosa Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241001522296 Erithacus rubecula Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016059 Facial pain Diseases 0.000 description 2
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 2
- 208000027109 Headache disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- LWYXFDXUMVEZKS-ZVFOLQIPSA-N Methysergide maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 LWYXFDXUMVEZKS-ZVFOLQIPSA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 208000037158 Partial Epilepsies Diseases 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 2
- 238000009106 abortive therapy Methods 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 229960000571 acetazolamide Drugs 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- 229940025141 anafranil Drugs 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940089231 butorphanol nasal spray Drugs 0.000 description 2
- 229940095559 cafergot Drugs 0.000 description 2
- 229940088033 calan Drugs 0.000 description 2
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 description 2
- 229940088029 cardizem Drugs 0.000 description 2
- 229940053548 centrally acting sympathomimetics Drugs 0.000 description 2
- CJMJLDQKTOJACI-SEUSHGJOSA-N chembl2448612 Chemical compound OC(=O)C(O)C(O)C(O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 CJMJLDQKTOJACI-SEUSHGJOSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960004606 clomipramine Drugs 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 229940088505 compazine Drugs 0.000 description 2
- 229940116800 covera Drugs 0.000 description 2
- 208000012790 cranial neuralgia Diseases 0.000 description 2
- 229950007605 dapitant Drugs 0.000 description 2
- 229940089052 depakene Drugs 0.000 description 2
- 229940099242 dexedrine Drugs 0.000 description 2
- 229940119751 dextroamphetamine sulfate Drugs 0.000 description 2
- 229940028367 dhe-45 Drugs 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- ATKXDQOHNICLQW-UHFFFAOYSA-N dichloralphenazone Chemical compound OC(O)C(Cl)(Cl)Cl.OC(O)C(Cl)(Cl)Cl.CN1C(C)=CC(=O)N1C1=CC=CC=C1 ATKXDQOHNICLQW-UHFFFAOYSA-N 0.000 description 2
- 229960005422 dichloralphenazone Drugs 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 229960004704 dihydroergotamine Drugs 0.000 description 2
- LUZRJRNZXALNLM-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 LUZRJRNZXALNLM-JGRZULCMSA-N 0.000 description 2
- 229960000807 dihydroergotamine mesylate Drugs 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 229940028937 divalproex sodium Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- LRMJAFKKJLRDLE-UHFFFAOYSA-N dotarizine Chemical compound O1CCOC1(C=1C=CC=CC=1)CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 LRMJAFKKJLRDLE-UHFFFAOYSA-N 0.000 description 2
- 229950005624 dotarizine Drugs 0.000 description 2
- 229960005426 doxepin Drugs 0.000 description 2
- 229940011681 elavil Drugs 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 229940089481 ergomar Drugs 0.000 description 2
- CJMJLDQKTOJACI-BGQAIRJTSA-N ergotamine d-tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)=C1)C)C1=CC=CC=C1 CJMJLDQKTOJACI-BGQAIRJTSA-N 0.000 description 2
- 229940074099 esgic Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229940103472 etrafon Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229940032148 fioricet Drugs 0.000 description 2
- 229940042721 fiorinal Drugs 0.000 description 2
- 229960004038 fluvoxamine Drugs 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940088024 isoptin Drugs 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 229950005286 lanepitant Drugs 0.000 description 2
- GMTYREVWZXJPLF-SXWPHCFWSA-N levo-bc-2627 tartrate Chemical compound OC(=O)C(O)C(O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-SXWPHCFWSA-N 0.000 description 2
- 229940087372 limbitrol Drugs 0.000 description 2
- 238000010234 longitudinal analysis Methods 0.000 description 2
- 229940089504 lopressor Drugs 0.000 description 2
- 229940009622 luvox Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229940037361 midrin Drugs 0.000 description 2
- 229940009945 migranal Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- KJNFMGMNZKFGIE-UHFFFAOYSA-N n-(4-hydroxyphenyl)acetamide;5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)NC1=CC=C(O)C=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O KJNFMGMNZKFGIE-UHFFFAOYSA-N 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 229940087524 nardil Drugs 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 229940072228 neurontin Drugs 0.000 description 2
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 229940072101 nimotop Drugs 0.000 description 2
- ITIXDWVDFFXNEG-JHOUSYSJSA-N olcegepant Chemical compound C([C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCN(CC1)C=1C=CN=CC=1)NC(=O)N1CCC(CC1)N1C(NC2=CC=CC=C2C1)=O)C1=CC(Br)=C(O)C(Br)=C1 ITIXDWVDFFXNEG-JHOUSYSJSA-N 0.000 description 2
- 229940041678 oral spray Drugs 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 229940055692 pamelor Drugs 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229960000964 phenelzine Drugs 0.000 description 2
- 229940107333 phenergan Drugs 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229940080693 reglan Drugs 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000009118 salvage therapy Methods 0.000 description 2
- 229940081989 sansert Drugs 0.000 description 2
- 229940100992 sarafem Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- YHKQUERNJBHAGZ-RWHAEUCFSA-M sodium;(4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine;n-(4-hyd Chemical compound [Na+].Cl.Cl.OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC.C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 YHKQUERNJBHAGZ-RWHAEUCFSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000003890 substance P antagonist Substances 0.000 description 2
- WJXREUZUPGMAII-UHFFFAOYSA-N sulfurazidic acid Chemical compound OS(=O)(=O)N=[N+]=[N-] WJXREUZUPGMAII-UHFFFAOYSA-N 0.000 description 2
- 229940108485 tenormin Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940041597 tofranil Drugs 0.000 description 2
- 229960001288 triamterene Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 229940055010 verelan Drugs 0.000 description 2
- 229940000146 vicodin Drugs 0.000 description 2
- 229940063674 voltaren Drugs 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 229960002911 zonisamide Drugs 0.000 description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010050258 Basilar migraine Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 206010020802 Hypertensive crisis Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001590997 Moolgarda engeli Species 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000005056 Ophthalmoplegic Migraine Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010052784 Retinal migraine Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- 206010040108 Serotonin syndrome Diseases 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- YUMNNMSNSLHINV-UHFFFAOYSA-N chloro sulfamate Chemical compound NS(=O)(=O)OCl YUMNNMSNSLHINV-UHFFFAOYSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 201000005108 complex partial epilepsy Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229940080861 demerol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 229960001903 ergotamine tartrate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010067039 familial hemiplegic migraine Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229950007692 lomerizine Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000017420 migraine with brainstem aura Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 201000002852 simple partial epilepsy Diseases 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940035305 topamax Drugs 0.000 description 1
- 229940097017 topiramate 100 mg Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35989402P | 2002-02-26 | 2002-02-26 | |
| US60/359,894 | 2002-02-26 | ||
| PCT/US2003/005463 WO2003072138A1 (en) | 2002-02-26 | 2003-02-25 | Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003213242A1 true AU2003213242A1 (en) | 2003-09-09 |
Family
ID=27663315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003213242A Abandoned AU2003213242A1 (en) | 2002-02-26 | 2003-02-25 | Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20030225002A1 (https=) |
| EP (1) | EP1478400A1 (https=) |
| JP (1) | JP2005518439A (https=) |
| KR (1) | KR101008326B1 (https=) |
| CN (1) | CN100352506C (https=) |
| AU (1) | AU2003213242A1 (https=) |
| BR (1) | BR0307951A (https=) |
| CA (1) | CA2419989A1 (https=) |
| HR (1) | HRP20040846A2 (https=) |
| IL (2) | IL163720A0 (https=) |
| MX (1) | MXPA04008259A (https=) |
| NO (1) | NO20043984L (https=) |
| NZ (1) | NZ534874A (https=) |
| PL (1) | PL372393A1 (https=) |
| RU (1) | RU2004126093A (https=) |
| UA (1) | UA81110C2 (https=) |
| WO (1) | WO2003072138A1 (https=) |
| ZA (1) | ZA200407729B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
| CA2556424A1 (en) | 2004-02-17 | 2005-09-01 | Sepracor Inc. | Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites |
| US20060233892A1 (en) * | 2005-04-19 | 2006-10-19 | Curt Hendrix | Topiramate compositions for treatment of headache |
| US20060252745A1 (en) * | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| FR2890564B1 (fr) * | 2005-09-09 | 2007-10-19 | Servier Lab | Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent |
| EA023147B1 (ru) * | 2006-04-13 | 2016-04-29 | Тева Фармасьютикалс Интернешнл Гмбх | Трансдермальный пластырь для лечения мигрени |
| EP2023894A4 (en) * | 2006-04-25 | 2010-10-20 | Applied Pharma Res | FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE |
| WO2008027557A2 (en) | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| SI2124556T1 (sl) | 2006-10-09 | 2015-01-30 | Charleston Laboratories, Inc. | Farmacevtske sestave |
| US8298576B2 (en) | 2006-11-17 | 2012-10-30 | Supernus Pharmaceuticals, Inc. | Sustained-release formulations of topiramate |
| MX2009003911A (es) * | 2006-12-04 | 2009-05-28 | Supernus Pharmaceuticals Inc | Formulaciones de liberacion inmediata, mejoradas de topiramato. |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| EP3090743A1 (en) | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
| JP5690732B2 (ja) * | 2008-09-17 | 2015-03-25 | ザ マクリーン ホスピタル コーポレーション | 群発頭痛障害を治療するための方法及びキット |
| CA2767576C (en) | 2009-07-08 | 2020-03-10 | Charleston Laboratories Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CA3055170A1 (en) | 2016-03-04 | 2017-09-08 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| WO2018067330A1 (en) * | 2016-10-06 | 2018-04-12 | Baylor College Of Medicine | Photochromatic modulation with fluorescein for the treatment of photo-oculodynia and blepharospasm |
| EP3955933B1 (en) * | 2019-04-15 | 2023-11-29 | Vistagen Therapeutics, Inc. | Treatment of migraine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| IL103172A (en) * | 1991-09-19 | 1997-01-10 | Mcneilab Inc | Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol |
| US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| US5998380A (en) * | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
| WO1998007447A1 (en) * | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| US20020015713A1 (en) * | 1996-10-24 | 2002-02-07 | Murdock Robert W. | Methods and transdermal compositions for pain relief |
| AU1930897A (en) * | 1997-03-03 | 1998-09-22 | Laboratoires Remilea | Plant extract compositions, method of preparation, and pharmaceutical comp ositions containing them |
| US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
| US5935933A (en) * | 1997-07-16 | 1999-08-10 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating neuropathic pain |
| US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
| GB9720270D0 (en) * | 1997-09-25 | 1997-11-26 | Pharmagene Lab Limited | Medicaments for the treatment of migraine |
| US6068999A (en) * | 1998-06-25 | 2000-05-30 | Hendrix; Curt | Dietary supplement for supporting cerebrovascular tone and treating migraine headaches |
| ATE279921T1 (de) * | 1999-01-19 | 2004-11-15 | Ortho Mcneil Pharm Inc | Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache |
| PL213323B1 (pl) * | 1999-08-20 | 2013-02-28 | Ortho Mcneil Pharm Inc | Kompozycja farmaceutyczna i jej zastosowanie |
-
2003
- 2003-02-25 RU RU2004126093/14A patent/RU2004126093A/ru not_active Application Discontinuation
- 2003-02-25 UA UA20040807114A patent/UA81110C2/uk unknown
- 2003-02-25 CN CNB038091135A patent/CN100352506C/zh not_active Expired - Lifetime
- 2003-02-25 IL IL16372003A patent/IL163720A0/xx unknown
- 2003-02-25 HR HR20040846A patent/HRP20040846A2/hr not_active Application Discontinuation
- 2003-02-25 US US10/373,488 patent/US20030225002A1/en not_active Abandoned
- 2003-02-25 NZ NZ534874A patent/NZ534874A/en not_active IP Right Cessation
- 2003-02-25 KR KR1020047013261A patent/KR101008326B1/ko not_active Expired - Fee Related
- 2003-02-25 BR BR0307951-1A patent/BR0307951A/pt not_active Application Discontinuation
- 2003-02-25 MX MXPA04008259A patent/MXPA04008259A/es unknown
- 2003-02-25 WO PCT/US2003/005463 patent/WO2003072138A1/en not_active Ceased
- 2003-02-25 JP JP2003570882A patent/JP2005518439A/ja active Pending
- 2003-02-25 PL PL03372393A patent/PL372393A1/xx not_active Application Discontinuation
- 2003-02-25 AU AU2003213242A patent/AU2003213242A1/en not_active Abandoned
- 2003-02-25 EP EP03709289A patent/EP1478400A1/en not_active Withdrawn
- 2003-02-26 CA CA002419989A patent/CA2419989A1/en not_active Abandoned
-
2004
- 2004-08-24 IL IL163720A patent/IL163720A/en active IP Right Grant
- 2004-09-23 ZA ZA200407729A patent/ZA200407729B/en unknown
- 2004-09-23 NO NO20043984A patent/NO20043984L/no unknown
-
2006
- 2006-12-08 US US11/608,276 patent/US20070099849A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1478400A1 (en) | 2004-11-24 |
| PL372393A1 (en) | 2005-07-25 |
| JP2005518439A (ja) | 2005-06-23 |
| CN100352506C (zh) | 2007-12-05 |
| IL163720A (en) | 2012-06-28 |
| NZ534874A (en) | 2007-03-30 |
| NO20043984L (no) | 2004-09-23 |
| KR20040091074A (ko) | 2004-10-27 |
| MXPA04008259A (es) | 2005-05-27 |
| US20030225002A1 (en) | 2003-12-04 |
| UA81110C2 (en) | 2007-12-10 |
| BR0307951A (pt) | 2004-12-21 |
| HRP20040846A2 (en) | 2005-06-30 |
| ZA200407729B (en) | 2006-06-28 |
| IL163720A0 (en) | 2005-12-18 |
| CA2419989A1 (en) | 2003-08-05 |
| RU2004126093A (ru) | 2005-04-10 |
| CN1646168A (zh) | 2005-07-27 |
| US20070099849A1 (en) | 2007-05-03 |
| KR101008326B1 (ko) | 2011-01-13 |
| WO2003072138A1 (en) | 2003-09-04 |
| HK1080731A1 (en) | 2006-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030225002A1 (en) | Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents | |
| US6627653B2 (en) | Anticonvulsant derivatives useful for the treatment of depression | |
| US20250302734A1 (en) | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults | |
| AU782344B2 (en) | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders | |
| Trivedi et al. | Original Research A Randomized Controlled Trial of the Efficacy and Safety | |
| US6620819B2 (en) | Anticonvulsant derivatives useful in treating psychosis | |
| US20030060423A1 (en) | Co-therapy for the treatment of dementia and associated behavioral manifestations comprising anticonvulsant derivatives and acetylcholinesterase inhibitors | |
| KR20180054584A (ko) | 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법 | |
| US6486198B1 (en) | Compounds and methods for the treatment of post traumatic stress disorder | |
| Pabis et al. | Pharmacotherapy of aggressive behavior | |
| WO2000042995A2 (en) | Use of anticonvulsant derivatives for treating transformed migraine | |
| US20030092636A1 (en) | Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium | |
| HK1080731B (en) | Use of a combination of anticonvulsant derivatives and anti-migraine agents in manufacture of medicaments | |
| EP4615426A1 (en) | Compositions and methods for treating insomnia | |
| Tomson et al. | The impact of background antiepileptic drugs on the efficacy and safety of pregabalin in treating partial-onset seizures: a post hoc analysis of combined clinical trials | |
| AU2002307542A1 (en) | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics | |
| MXPA99003258A (en) | Anticonvulsant derivatives useful in treating neuropathic pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |